article
Developing IL-15 superagonists for cancer therapy
Richard Sachse discusses how immunotherapies targeting interleukin 15 (IL-15) signalling can be optimised to enhance their efficacy and limit off-target effects.
List view / Grid view
Cancer
article
The next generation of cancer immunotherapies: re-exploring the IL-2 pathway
In this article, Dr Bruce Dezube explains why new cancer immunotherapy drugs that utilise the IL-2 pathway with lower side effects could offer more benefits compared to high-dose IL-2 treatment.
article
Novel biomarker technology for cancer diagnostics
A new way of identifying cancer biomarkers has been developed by researchers at Lund University in Sweden. The new technology allows very sensitive, quick and cost-effective identification of cancer biomarkers. Nikki Withers spoke to Professor Carl Borrebaeck, who discusses how the researchers demonstrated the power of combining proteomics with genomics.
article
Advancing cell therapies with engineered Tregs
Regulatory T cells (Tregs) play a key role in regulating our immune system and inflammatory processes. Sangamo Therapeutics is evaluating the potential of CAR-Tregs (Tregs genetically modified with a chimeric antigen receptor, or CAR) for the development of therapies for immunological diseases, such as Crohn’s disease and multiple sclerosis, as…
article
Bispecific antibodies: the next generation of immuno-oncology drugs
Taylor B Guo, Chief Scientific Officer at I-Mab, describes the potential benefits of bispecific antibodies for cancer therapy and how their dual targeting mechanisms of action may drive their emergence as the next generation of immuno-oncology drugs.
article
Oncology meets immunology – antibody-mediated regulation of the immune response
In this article, Aparajita Dubey discusses the role of antibodies in regulating the immune system and highlights key features that need to be considered for drug development and how this can be applied to cancer therapy.
article
Assays In-Depth Focus 2020
In this In-Depth Focus find articles exploring the roles of key proteins implicated in Alzheimer's disease and a new technology enabling the identification of novel cancer biomarkers.
article
Innovations for next-generation antibody-drug conjugates
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.
news
Finding order in the chaos of cancer mutations
Scientists observed that different cancers undergo the same genetic mutations at similar stages of evolution, the findings could become part of an ‘evolutionary rule book’ which would theoretically enable the prediction and prevention of cancer’s next evolutionary move.
news
Novel small molecules inhibit cancer-associated enzymes in cells
A drug-like compound that can inhibit a key family of enzymes associated with several types of cancer has been developed and tested successfully in cells.
news
Novel targeted treatment shows efficacy in treating high-risk solid tumours
The prodrug developed by researchers caused long-term remission in all murine models of high-risk or drug-resistant cancers with fewer side-effects than a comparable drug.
news
Researchers identify over 550 cancer-driving genes
Computational analysis has been used by researchers to examine 66 types of cancer and identify 568 genes that drive tumour development.
news
Researchers treat diffuse intrinsic pontine glioma in mice
Researchers have treated diffuse intrinsic pontine glioma (DIPG), a fatal childhood brain cancer, in mice by targeting two metabolic pathways.
news
Over 200 genes implicated in glioblastoma tumour growth
A study has identified more than 200 genes that drive the progression of glioblastoma and which the researchers say present drug targets.
article
Five developments in oncology targets
Drug Target Review explores some of the newest oncologic drug targets, including those for glioblastoma, lung cancer and breast cancer.